Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew J Muir

Showing results (151-160 of 187) with videos related to

Pageof 19
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 25, 2020
Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing CholangitisPalak J Trivedi, Andrew J Muir, Cynthia Levy, et al.
Hepatology (Baltimore, Md.)|August 4, 2020
A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing CholangitisYevgeniy Gindin, Chuhan Chung, Zhaoshi Jiang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 5, 2020
Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus InfectionEli Zuckerman, Julio A Gutierrez, Douglas E Dylla, et al.
Gastroenterology|July 6, 2010
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1Stefan Zeuzem, Mark S Sulkowski, Eric J Lawitz, et al.
Hepatology (Baltimore, Md.)|January 29, 2011
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVRAlexander J Thompson, Rosanna Santoro, Valeria Piazzolla, et al.
Hepatology (Baltimore, Md.)|November 21, 2017
Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PROZobair M Younossi, Arian Afendy, Maria Stepanova, et al.
The New England Journal of Medicine|April 9, 2010
Telaprevir for previously treated chronic HCV infectionJohn G McHutchison, Michael P Manns, Andrew J Muir, et al.
Nature|February 23, 2010
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis CJacques Fellay, Alexander J Thompson, Dongliang Ge, et al.
Hepatology (Baltimore, Md.)|December 6, 2019
A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C InfectionRae Jean Proeschold-Bell, Donna M Evon, Jia Yao, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 9, 2014
Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL studyMichael T Melia, Norbert Bräu, Fred Poordad, et al.
Pageof 19

Showing results (151-160 of 187) with videos related to

Sort By:
Pageof 19
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 25, 2020
Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing CholangitisPalak J Trivedi, Andrew J Muir, Cynthia Levy, et al.
Hepatology (Baltimore, Md.)|August 4, 2020
A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing CholangitisYevgeniy Gindin, Chuhan Chung, Zhaoshi Jiang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 5, 2020
Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus InfectionEli Zuckerman, Julio A Gutierrez, Douglas E Dylla, et al.
Gastroenterology|July 6, 2010
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1Stefan Zeuzem, Mark S Sulkowski, Eric J Lawitz, et al.
Hepatology (Baltimore, Md.)|January 29, 2011
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVRAlexander J Thompson, Rosanna Santoro, Valeria Piazzolla, et al.
Hepatology (Baltimore, Md.)|November 21, 2017
Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PROZobair M Younossi, Arian Afendy, Maria Stepanova, et al.
The New England Journal of Medicine|April 9, 2010
Telaprevir for previously treated chronic HCV infectionJohn G McHutchison, Michael P Manns, Andrew J Muir, et al.
Nature|February 23, 2010
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis CJacques Fellay, Alexander J Thompson, Dongliang Ge, et al.
Hepatology (Baltimore, Md.)|December 6, 2019
A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C InfectionRae Jean Proeschold-Bell, Donna M Evon, Jia Yao, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 9, 2014
Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL studyMichael T Melia, Norbert Bräu, Fred Poordad, et al.
Pageof 19